WSW, NY, March 31st, 2026, FinanceWire
When a clinical-stage oncology company quietly racks up one win after another, those who pay attention often catch the best moves before Wall Street wakes up. That’s exactly where Alpha Tau Medical (NASDAQ: DRTS) might be finding itself today.
On March 31, 2026, the company announced that updated results from two first-in-human Jerusalem trials of its Alpha DaRT therapy in pancreatic cancer patients will be delivered as an oral podium presentation at Digestive Disease Week (DDW) 2026—the world’s premier gastroenterology meeting. The talk, scheduled for May 2 in the Pancreatic Cancer I session, will be given by Dr. Harold Jacob, a leading advanced endoscopist at Hadassah University Medical Center. It marks the first time Alpha DaRT pancreatic data has earned this level of spotlight at a major GI conference.
This isn’t a standalone headline. It’s the latest chapter in a year of genuine, accelerating momentum for Alpha Tau. The company isn’t just navigating the long clinical grind – it’s executing across multiple fronts at once, turning a novel Israeli-born physics breakthrough into a potential new approach for treating some of oncology’s hardest-to-crack solid tumors.
At its core, Alpha DaRT is elegantly simple yet powerful. Tiny seeds coated with radium-224 are placed directly inside the tumor – often through the same quick endoscopic ultrasound procedure that gastroenterologists perform routinely. The radium decays over days, releasing short-lived daughter atoms that diffuse a few millimeters through the tumor tissue. These atoms emit ultra-short-range alpha particles that deliver high-energy damage to cancer-cell DNA over just a few cell widths, with limited exposure to surrounding healthy tissue and early data suggesting a comparatively immune-preserving profile. It’s radiation delivered from the inside out, designed to kill tumors while minimizing the collateral damage typical of external-beam therapy or systemic radiopharmaceuticals.
That mechanism is already producing encouraging signals. Final data from the Montreal first-in-human pancreatic study, presented at ASCO GI in January 2026, showed an 81% disease control rate (rising to 87% when excluding the two lowest initial doses) and, notably, immune markers that remained stable one month later—contrasting with the immune-suppressing effects often seen with conventional radiation. Early combination data in recurrent head-and-neck cancer with Merck’s Keytruda showed a 75% systemic objective response rate in a small cohort, compared with a 19% systemic ORR reported in a comparable population in KEYNOTE-048. These kinds of immune-preserving signals matter in an era where checkpoint inhibitors have become foundational across many cancers.
The broader pipeline is moving quickly. Alpha Tau now has five concurrent FDA-approved Investigational Device Exemption trials running in the United States: a pivotal ReSTART study in recurrent cutaneous squamous cell carcinoma (nearing full enrollment), the IMPACT pancreatic pilot combining Alpha DaRT with chemotherapy (with recruitment targeted for completion by the end of Q1 2026), a recurrent glioblastoma feasibility study (with the first brain patient treated in December 2025 at Ohio State), an immunocompromised skin cancer trial, and a locally recurrent prostate cancer pilot approved in December. On the regulatory side, the company submitted the first module of its modular Pre-Market Approval application to the FDA in January for recurrent cSCC, and it holds Breakthrough Device Designation in multiple indications.
Most notably, in late February 2026 Japan’s Ministry of Health granted marketing approval for Alpha DaRT for unresectable or locally recurrent head-and-neck cancer – the first regulatory authorization of the platform outside Israel. This gives Alpha Tau an early commercial foothold and a meaningful validation point as it advances in other markets. Meanwhile, manufacturing is scaling: the company received its radioactive materials license for a new U.S. facility in Hudson, New Hampshire last October, with Phase 1 capacity aimed at approximately 400,000 sources annually.
Financially, Alpha Tau remains pre-revenue but solidly capitalized. It ended 2025 with approximately $76.9 million in cash, providing runway well into key 2026 data readouts without immediate financing pressure. The stock, recently trading in the mid-$6 range, implies a market capitalization of roughly $600 million—still modest when compared with the multi-billion-dollar valuations paid in recent radiopharmaceutical acquisitions by large pharmaceutical companies. Those deals have largely focused on systemic radioligand therapies for metastatic disease; Alpha DaRT offers a localized approach that could complement existing treatment paradigms, particularly in solid tumors where systemic therapies may face limitations in penetration.
Of course, balance is important. Alpha DaRT is still early. The pancreatic data come from small feasibility studies, larger randomized trials will be needed, and regulatory timelines always carry risk. Competition in oncology remains intense, and not every promising signal translates into approval.
Yet the setup is increasingly defined: a differentiated, physics-based mechanism that is less dependent on tumor-specific molecular targeting, multiple high-unmet-need indications under active study, a first commercial market in Japan, a clear regulatory pathway in the U.S., manufacturing infrastructure in place, and growing engagement from key opinion leaders presenting data at major medical conferences.
Today’s DDW oral acceptance is the kind of incremental but visible milestone that builds credibility with the specialists who would ultimately adopt the therapy. When Dr. Jacob presents the data in May, the gastroenterology community will get a closer look at how Alpha DaRT could integrate into real-world pancreatic cancer care.
For those watching the Company, the broader picture may be more important. 2026 is shaping up as a year of continued execution – study completions, data readouts, regulatory progress, and potential strategic interest in a sector where targeted radiation is drawing increasing attention.
Alpha Tau didn’t arrive here overnight. It has steadily advanced from early scientific concept to a multi-indication platform with growing clinical and regulatory traction. The DDW news is simply the latest signal that momentum is building – and for those focused on execution-driven stories, DRTS may be worth watching while it remains under the radar.
Recent News Highlights from Alpha Tau (NASDAQ:DRTS)
Alpha Tau Announces Full Year 2025 Financial Results and Provides Corporate Update
Important Disclaimers and Disclosures: The author, Wall Street Wire, is a content and media technology platform that connects the market with under-the-radar companies. The platform operates a network of industry-focused media channels spanning finance, biopharma, cyber, AI, and additional sectors, delivering insights on both broader market developments and emerging or overlooked companies. The content above is a form of paid promotional content and advertising. Wall Street Wire receives cash compensation from Oramed Pharmaceuticals Inc for promotional media services provided on an ongoing subscription basis to to Alpha Tau Medical Ltd. This content is for informational purposes only and does not constitute financial or investment advice. Wall Street Wire is not a broker-dealer or investment adviser. Full compensation details, information about the operator of Wall Street Wire, and the complete set of disclaimers and disclosures applicable to this content are available at: wallstwire.ai/disclosures. Market size figures or other estimates referenced in this article are quoted from publicly available sources; we do not independently verify or endorse them, and additional figures or estimates may exist. This article should not be considered an official communication of the issuer.